Tan, D. S. P., Ng, M. C. H., Subbiah, V., Messersmith, W. A., Strickler, J. H., Diermayr, V., … Prativadibhayankaram, V. S. (2023). A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Tan, David Shao Peng, Matthew C. H. Ng, Vivek Subbiah, Wells A. Messersmith, John H. Strickler, Veronica Diermayr, Julienne Cometa, et al. “A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Tan DSP, Ng MCH, Subbiah V, Messersmith WA, Strickler JH, Diermayr V, et al. A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Tan, David Shao Peng, et al. “A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Tan DSP, Ng MCH, Subbiah V, Messersmith WA, Strickler JH, Diermayr V, Cometa J, Blanchard S, Nellore R, Pendharkar V, Gan BH, Rozaini NN, Koh C, Sarma S, Poh HM, Lezhava A, Prativadibhayankaram VS. A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours. JOURNAL OF CLINICAL ONCOLOGY. 2023.